Reuters -- GTx Inc said an independent data safety monitoring committee has recommended the continuation of the late-stage trials of the company’s experimental drug, toremifene, for the prevention of prostate cancer.
Reuters -- GTx Inc said an independent data safety monitoring committee has recommended the continuation of the late-stage trials of the company’s experimental drug, toremifene, for the prevention of prostate cancer.
